These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
785 related articles for article (PubMed ID: 28145904)
1. Overcoming therapeutic resistance in glioblastoma: the way forward. Osuka S; Van Meir EG J Clin Invest; 2017 Feb; 127(2):415-426. PubMed ID: 28145904 [TBL] [Abstract][Full Text] [Related]
2. Differential expression of MicroRNAs in patients with glioblastoma after concomitant chemoradiotherapy. Park EC; Kim G; Jung J; Wang K; Lee S; Jeon SS; Lee ZW; Kim SI; Kim S; Oh YT; Shin JH; Jang HS; Choi BO; Kim GH OMICS; 2013 May; 17(5):259-68. PubMed ID: 23586679 [TBL] [Abstract][Full Text] [Related]
3. The role of octamer binding transcription factors in glioblastoma multiforme. Rooj AK; Bronisz A; Godlewski J Biochim Biophys Acta; 2016 Jun; 1859(6):805-11. PubMed ID: 26968235 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic strategies for inhibiting invasion in glioblastoma. Drappatz J; Norden AD; Wen PY Expert Rev Neurother; 2009 Apr; 9(4):519-34. PubMed ID: 19344303 [TBL] [Abstract][Full Text] [Related]
11. Recognizing and correcting failures in glioblastoma treatment. Shah AH; Graham R; Bregy A; Thambuswamy M; Komotar RJ Cancer Invest; 2014 Jul; 32(6):299-302. PubMed ID: 24766304 [TBL] [Abstract][Full Text] [Related]
12. Knockdown of long non-coding RNA XIST exerts tumor-suppressive functions in human glioblastoma stem cells by up-regulating miR-152. Yao Y; Ma J; Xue Y; Wang P; Li Z; Liu J; Chen L; Xi Z; Teng H; Wang Z; Li Z; Liu Y Cancer Lett; 2015 Apr; 359(1):75-86. PubMed ID: 25578780 [TBL] [Abstract][Full Text] [Related]
13. The pro-tumorigenic effects of metabolic alterations in glioblastoma including brain tumor initiating cells. Landis CJ; Tran AN; Scott SE; Griguer C; Hjelmeland AB Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):175-188. PubMed ID: 29378228 [TBL] [Abstract][Full Text] [Related]
14. Epigenetic regulation of cancer stem cell and tumorigenesis. Zhu K; Xie V; Huang S Adv Cancer Res; 2020; 148():1-26. PubMed ID: 32723561 [TBL] [Abstract][Full Text] [Related]
16. The Role of Mesenchymal Reprogramming in Malignant Clonal Evolution and Intra-Tumoral Heterogeneity in Glioblastoma. Wu Q; Berglund AE; Macaulay RJ; Etame AB Cells; 2024 May; 13(11):. PubMed ID: 38891074 [TBL] [Abstract][Full Text] [Related]
17. Glioblastoma cancer stem cells--from concept to clinical application. Stopschinski BE; Beier CP; Beier D Cancer Lett; 2013 Sep; 338(1):32-40. PubMed ID: 22668828 [TBL] [Abstract][Full Text] [Related]
18. Glioblastoma cancer stem cells: Biomarker and therapeutic advances. Pointer KB; Clark PA; Zorniak M; Alrfaei BM; Kuo JS Neurochem Int; 2014 May; 71():1-7. PubMed ID: 24657832 [TBL] [Abstract][Full Text] [Related]
19. Intratumoral Genetic and Functional Heterogeneity in Pediatric Glioblastoma. Hoffman M; Gillmor AH; Kunz DJ; Johnston MJ; Nikolic A; Narta K; Zarrei M; King J; Ellestad K; Dang NH; Cavalli FMG; Kushida MM; Coutinho FJ; Zhu Y; Luu B; Ma Y; Mungall AJ; Moore R; Marra MA; Taylor MD; Pugh TJ; Dirks PB; Strother D; Lafay-Cousin L; Resnick AC; Scherer S; Senger DL; Simons BD; Chan JA; Morrissy AS; Gallo M Cancer Res; 2019 May; 79(9):2111-2123. PubMed ID: 30877103 [TBL] [Abstract][Full Text] [Related]
20. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Kim H; Zheng S; Amini SS; Virk SM; Mikkelsen T; Brat DJ; Grimsby J; Sougnez C; Muller F; Hu J; Sloan AE; Cohen ML; Van Meir EG; Scarpace L; Laird PW; Weinstein JN; Lander ES; Gabriel S; Getz G; Meyerson M; Chin L; Barnholtz-Sloan JS; Verhaak RG Genome Res; 2015 Mar; 25(3):316-27. PubMed ID: 25650244 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]